WallStSmart

Lineage, Inc. Common Stock (LINE)vsChiron Real Estate Inc. (XRN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Lineage, Inc. Common Stock generates 3437% more annual revenue ($5.36B vs $151.53M). LINE leads profitability with a -2.7% profit margin vs -5.1%. XRN earns a higher WallStSmart Score of 45/100 (D+).

LINE

Avoid

34

out of 100

Grade: F

Growth: 4.0Profit: 3.0Value: 5.0Quality: 3.0
Piotroski: 2/9Altman Z: 0.67

XRN

Hold

45

out of 100

Grade: D+

Growth: 5.3Profit: 4.0Value: 4.0Quality: 3.5
Piotroski: 4/9Altman Z: -0.36

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

LINE1 strengths · Avg: 10.0/10
Price/BookValuation
1.2x10/10

Reasonable price relative to book value

XRN2 strengths · Avg: 9.0/10
Price/BookValuation
1.2x10/10

Reasonable price relative to book value

Operating MarginProfitability
23.4%8/10

Strong operational efficiency at 23.4%

Areas to Watch

LINE4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.4%4/10

0.4% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Operating MarginProfitability
3.3%3/10

Operating margin of 3.3%

Debt/EquityHealth
1.013/10

Elevated debt levels

XRN4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$533.09M3/10

Smaller company, higher risk/reward

Debt/EquityHealth
1.363/10

Elevated debt levels

PEG RatioValuation
5.092/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : LINE

The strongest argument for LINE centers on Price/Book.

Bull Case : XRN

The strongest argument for XRN centers on Price/Book, Operating Margin. Revenue growth of 10.1% demonstrates continued momentum.

Bear Case : LINE

The primary concerns for LINE are Revenue Growth, EPS Growth, Operating Margin.

Bear Case : XRN

The primary concerns for XRN are EPS Growth, Market Cap, Debt/Equity.

Key Dynamics to Monitor

XRN is growing revenue faster at 10.1% — sustainability is the question.

XRN generates stronger free cash flow (11M), providing more financial flexibility.

Monitor REIT - INDUSTRIAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

XRN scores higher overall (45/100 vs 34/100) and 10.1% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Lineage, Inc. Common Stock

REAL ESTATE · REIT - INDUSTRIAL · USA

Lineage, Inc. (Ticker: LINE) is an innovative biotechnology company specializing in regenerative medicine, with a focus on developing state-of-the-art cell therapies for conditions such as ocular diseases, spinal cord injuries, and various cancers. Leveraging its proprietary technologies and strong strategic partnerships, Lineage aims to revolutionize patient care with pioneering therapeutic solutions. The company’s dedication to advancing its diverse product pipeline and accelerating clinical trials positions it as a compelling investment prospect for institutional investors looking to engage at the cutting edge of healthcare advancements.

Visit Website →

Chiron Real Estate Inc.

REAL ESTATE · REIT - HEALTHCARE FACILITIES · USA

Chiron Real Estate Inc. is a net-lease medical REIT that acquires healthcare facilities and leases those facilities to physician groups and regional and national healthcare systems.

Want to dig deeper into these stocks?